O
CLVS

OppenheimerFunds’s Clovis Oncology, Inc. CLVS Stock Holding History

OppenheimerFunds’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-117,806
Closed -$6.22M – 1830
2018
Q1 		$6.22M Sell
117,806
-125
-0.1% -$7.29K 0.01% 745
2017
Q4 		$8.02M Sell
117,931
-330
-0.3% -$23.1K 0.01% 762
2017
Q3 		$9.74M Sell
118,261
-5,003
-4% -$397K 0.01% 743
2017
Q2 		$11.5M Sell
123,264
-28,976
-19% -$1.77M 0.01% 710
2017
Q1 		$9.69M Buy
152,240
+6,344
+4% +$386K 0.01% 766
2016
Q4 		$6.48M Buy
+145,896
New +$5.13M 0.01% 810
2016
Q2 		– Sell
-1,246,660
Closed -$23.9M – 1737
2016
Q1 		$23.9M Buy
1,246,660
+1,150
+0.1% +$24.3K 0.03% 506
2015
Q4 		$43.6M Sell
1,245,510
-102,300
-8% -$6.6M 0.06% 366
2015
Q3 		$124M Sell
1,347,810
-169,580
-11% -$14.7M 0.17% 155
2015
Q2 		$133M Buy
1,517,390
+20,140
+1% +$1.72M 0.15% 169
2015
Q1 		$111M Sell
1,497,250
-279,724
-16% -$19.8M 0.12% 199
2014
Q4 		$99.5M Sell
1,776,974
-410
-0% -$21.5K 0.11% 213
2014
Q3 		$80.6M Buy
1,777,384
+580,202
+48% +$24.2M 0.09% 240
2014
Q2 		$49.6M Buy
1,197,182
+346,580
+41% +$17.9M 0.06% 352
2014
Q1 		$58.9M Buy
+850,602
New +$62.5M 0.07% 303

Other funds holding CLVS

PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

OppenheimerFunds's CLVS Position: Q2 2018 in Review

OppenheimerFunds sold out of Clovis Oncology, Inc. (CLVS) in Q2 2018, closing a stake of 117,806 shares — an estimated $6.22M sold.

OppenheimerFunds first reported a position in CLVS in Q1 2014 and held it in 15 quarters. The position peaked at $133M in Q2 2015. 210 funds tracked by Wall St. Rank hold CLVS as of Q2 2018.

  • OppenheimerFunds reported no remaining Clovis Oncology, Inc. position as of Q2 2018 after selling out during the quarter.
  • OppenheimerFunds sold 117,806 Clovis Oncology, Inc. shares in Q2 2018, an estimated $6.22M.
  • OppenheimerFunds first reported a position in Clovis Oncology, Inc. in Q1 2014 and held it in 15 quarters.
  • OppenheimerFunds's Clovis Oncology, Inc. position peaked at $133M in Q2 2015.
  • 210 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2018.

Based on OppenheimerFunds's 13F filing for Q2 2018, filed 13 Aug 2018.